

## **Pharmacy Drug Policy Checklist**

POLICY NAME Onpattro (patisiran) POLICY # 2666P

## Criteria

Coverage Criteria	
	Diagnosis of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis
	Documentation that the patient has a pathogenic TTR gene mutation (e.g., V30M)
	Age 18 years of age or older
	Presence of clinical signs and symptoms of the disease (e.g., nerve pain, movement disorders, heart disease, kidney disease)
	One of the following:
	<ul> <li>Patient has a baseline polyneuropathy disability (PND) score IIIb</li> </ul>
	Patient has a baseline familial amyloidotic polyneuropathy (FAP) Stage 1 or 2
	Prescribed by or in consultation with a neurologist (nervous system doctor)
Exclusion Criteria – Any of the following prevents coverage	
	Members concurrently taking any other hATTR therapy
	Members with previous liver transplant or severe kidney dysfunction